@Article{Ciebiada2009,
journal="Archives of Medical Science",
issn="1734-1922",
volume="5",
number="4",
year="2009",
title="Fexofenadine with either montelukast or a low-dose inhaled corticosteroid (fluticasone) in the treatment of patients with persistent allergic rhinitis and newly diagnosed asthma",
abstract=" Introduction:  Asthma often coexists in patients with persistent allergic rhinitis. The aim of this study was to investigate the effects of treatment with a combination of antihistamine (fexofenadine) and either an antileukotriene agent (montelukast) or a low-dose inhaled corticosteroid (fluticasone) in patients with persistent allergic rhinitis and newly diagnosed asthma.   Material and methods:  40 patients with persistent allergic rhinitis and newly diagnosed asthma received fexofenadine (120 mg/day) with fluticasone (200 \µg/day) for 6 weeks then fexofenadine (120 mg/day) with montelukast (10 mg/day) for another 6 weeks. Symptom scores, anterior rhinoscopy, spirometry and serum concentrations of soluble intercellular adhesion molecule 1 were evaluated before and after 6-week treatment periods.   Results:  The sICAM-1 serum concentration before treatment was 243.4 \±20.7 ng/ml, after treatment 221 \±20.4 ng/ml in the fexofenadine-fluticasone group; and before treatment was 240.9 \±19.8 ng/ml, after treatment 218.3 \±17.6 ng/ml in the fexofenadine-montelukast group. The total symptom score before treatment was 8.15 \±1.37, after treatment 3.625 \±0.77 in the fexofenadine-fluticasone group; and before treatment was 8.275 \±1.38, after treatment 3.55 \±0.78 in the fexofenadine-montelukast group. The asthma symptom score before treatment was 7.1 \±0.8, after treatment 2.1 \±1.5 in the fexofenadine-fluticasone group; and before treatment was 6.9 \±2.3, after treatment 1.7 \±1.4 in the fexofenadine-montelukast group.    Conclusions:  The combination of fexofenadine with either montelukast or a low-dose inhaled corticosteroid (fluticasone) equally reduces the serum sICAM-1 concentration and gives the same clinical effect in patients with persistent allergic rhinitis and newly diagnosed asthma.",
author="Ciebiada, Maciej
and Gorska-Ciebiada, Malgorzata
and Gorski, Pawel",
pages="564--569",
url="https://www.termedia.pl/Fexofenadine-with-either-montelukast-or-a-low-dose-inhaled-corticosteroid-fluticasone-in-the-treatment-of-patients-with-persistent-allergic-rhinitis-and-newly-diagnosed-asthma,19,13917,1,1.html"
}